Screener
ADMA Biologics ADMA CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Other current and non-current liabilities | (630) | (602) |
| Net cash provided by operating activities | 87,788 | 1,464 |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||
| Purchase of property and equipment | (4,799) | (7,123) |
| Acquisition of intangible assets | (53) | (124) |
| Proceeds on the sales of assets held for sale | 5,000 | - |
| Net cash provided by (used in) investing activities | 148 | (7,247) |
| CASH FLOWS FROM FINANCING ACTIVITIES: |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's capex?
- ADMA Biologics (ADMA) reported capex of $2.26M in Q2 2026.
- How has ADMA Biologics's capex changed year-over-year?
- ADMA Biologics's capex decreased by 6.9% year-over-year, from $2.42M to $2.26M.
- What is the long-term trend for ADMA Biologics's capex?
- Over 4 years (2021 to 2025), ADMA Biologics's capex has grown at a 13.7% compound annual growth rate (CAGR), from $13.51M to $22.58M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about ADMA Biologics's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude